Summer Liew
Westminster, CANPI 1205354602
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 626 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,255 and has fallen 70.6% since, to $1,249 in 2025.
Across 626 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sanofi$2K
- Johnson & Johnson$2K
- Regeneron Healthcare Solutions, Inc.$1K
- EPI Health, LLC$1K
- Sun Pharmaceutical Industries Inc.$1K
- plus $6K from 19 others
What the payments were for
- Consulting fees$8005%
- Food & beverage$14,35791%
- Education$5854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 147 | $3,345 |
| Sanofi | 52 | $1,692 |
| Johnson & Johnson | 76 | $1,598 |
| Regeneron Healthcare Solutions, Inc. | 45 | $1,051 |
| EPI Health, LLC | 5 | $1,050 |
| Sun Pharmaceutical Industries Inc. | 47 | $1,013 |
| UCB, Inc. | 42 | $859 |
| Pfizer | 36 | $617 |
| Lilly USA, LLC | 34 | $615 |
| E.r. Squibb & Sons, L.L.C. | 24 | $570 |
| Dermavant Sciences, Inc. | 11 | $551 |
| Janssen Scientific Affairs, LLC | 8 | $518 |
| Galderma Laboratories, L.p. | 24 | $507 |
| Amgen | 20 | $371 |
| Arcutis Biotherapeutics, Inc. | 10 | $357 |
| Incyte Corporation | 13 | $349 |
| Novartis | 9 | $232 |
| LEO Pharma Inc. | 4 | $89 |
| Almirall LLC | 4 | $83 |
| Genentech USA, Inc. | 1 | $73 |
| Kyowa Kirin, Inc. | 3 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $52 |
| Mayne Pharma Commercial LLC | 8 | $48 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 14 | $394 |
| Triamcinolone Acetonide | 15 | $186 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.